{"entity":{"id":"3sbio","kind":"company","name":"3SBio","aka":["Shenyang Sunshine Pharmaceutical","Sansheng Pharmaceutical"],"tldr":"3SBio is a Shenyang biologics company whose HER2 antibody inetetamab was approved in China in 2020 for HER2-positive metastatic breast cancer.","summary":"3SBio, listed in Hong Kong, is one of China's largest biologics makers, with a long-standing business in recombinant proteins (erythropoietin, thrombopoietin). In oncology its Fc-engineered HER2 antibody inetetamab (Cipterbin) was approved by the NMPA in June 2020 with vinorelbine for HER2-positive metastatic breast cancer. A 2025 licence of its PD-1 and VEGF bispecific antibody to Pfizer brought the company global attention.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.3sbio.com"}],"tags":["ctgov-sponsor","china"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["inetetamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"hq":"Shenyang, China","country":"CN","companyType":"biotech","website":"https://www.3sbio.com","stage":"public","investors":[],"funding":[]},"route":"/companies/3sbio/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"inetetamab","kind":"drug","name":"Inetetamab","route":"/drugs/inetetamab/"}]}}